Liposomal oxymatrine in hepatic fibrosis treatment: formulation, in vitro and in vivo assessment.
about
Detecting serum and urine metabolic profile changes of CCl4-liver fibrosis in rats at 12 weeks based on gas chromatography-mass spectrometry.Oxymatrine Induces Liver Injury through JNK Signalling Pathway Mediated by TNF-α In Vivo.A novel strategy of profiling the mechanism of herbal medicines by combining network pharmacology with plasma concentration determination and affinity constant measurement.Oxymatrine inhibits renal fibrosis of obstructive nephropathy by downregulating the TGF-β1-Smad3 pathway.Oxymatrine Causes Hepatotoxicity by Promoting the Phosphorylation of JNK and Induction of Endoplasmic Reticulum Stress Mediated by ROS in LO2 Cells.Oxymatrine exhibits anti-tumor activity in gastric cancer through inhibition of IL-21R-mediated JAK2/STAT3 pathway
P2860
Liposomal oxymatrine in hepatic fibrosis treatment: formulation, in vitro and in vivo assessment.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Liposomal oxymatrine in hepati ...... vitro and in vivo assessment.
@en
type
label
Liposomal oxymatrine in hepati ...... vitro and in vivo assessment.
@en
prefLabel
Liposomal oxymatrine in hepati ...... vitro and in vivo assessment.
@en
P2093
P2860
P1433
P1476
Liposomal oxymatrine in hepati ...... vitro and in vivo assessment.
@en
P2093
Dandan Shu
Shujuan Zhang
Subin Xiong
Tiechuang Wang
Weiguang Shan
P2860
P2888
P304
P356
10.1208/S12249-014-0086-Y
P407
P577
2014-02-12T00:00:00Z
P6179
1023763958